Home | Welcome to Contract Pharma   
Last Updated Monday, May 25 2015


Pharming Earns Santarus Milestone

Published November 26, 2012
Related Searches: Phase III Development
Pharming Group and Santarus have met the primary endpoint in a Phase III study of Ruconest (recombinant human C1 esterase inhibitor) for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema (HAE), triggering a $10 million milestone payment to Pharming. Pharming is eligible to receive an additional $5 million upon FDA acceptance of the BLA for review. The companies expect to submit the BLA for Ruconest in the 1H13.
Sijmen de Vries, Pharming’s chief executive officer, said, "We are pleased to have received this US$10 million milestone from our partner Santarus, which significantly strengthens our balance sheet and signals the beginning of a new chapter in the development of the company."

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On